Recently, the generic version of "Olaparib Tablets (150mg, 100mg)" developed by SinoT has been approved by NMPA(Registration # H20244039, H20244040).
Olaparib is the first PARP inhibitor originally developed by AstraZeneca. The tablets were approved by the FDA in 2017 and approved by NMPA in 2018. The indication includes epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer.In 2023, the sales volume of Olaparib tablets in the global market was about 70 million tablets, with sales of about US$3 billion. Since Jan. 1st
2020 when Olaparib Tablets was covered by national medical insurance, the sales volume of Olaparib Tablets in Chinese market was steady increased to 13 million tablets with sales of US$130 million in 2023.
About SinoT：
SinoT is a specialty pharma with focus on the research & development, commercialization and sale of complex generics and 505(b2) products. We dedicated to developing high quality medicines that meet with international standards. We’ll do more than our best to benefit the patients in the future.
Shanghai Head Office
99 Haike Road, Bldg. 3, 1st Flr., Pudong District Shanghai 201210, P.R. China
Manufacturing Site in Jiangsu
No. 163 Zhuhai Road, Haimen Area, Nantong City, Jiangsu Province
Focus on us
